K. Podar

发表

Kinase Cells Transformed by the Oncogenic TPR-MET Tyrosine A Novel Small Molecule Met Inhibitor Induces Apoptosis in Updated

J. Christensen, R. Salgia, Yuri B. Pride, 2003 .

Gene expression analysis of B‐lymphoma cells resistant and sensitive to bortezomib *

K. Anderson, N. Munshi, H. Ploegh, 2006, British journal of haematology.

Superoxide-dependent and -independent mitochondrial signaling during apoptosis in multiple myeloma cells

K. Anderson, N. Munshi, N. Mitsiades, 2003, Oncogene.

The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance.

M. Sporn, K. Anderson, N. Munshi, 2004, Blood.

Targeting Mcl-1 for multiple myeloma (MM) therapy: drug-induced generation of Mcl-1 fragment Mcl-1(128-350) triggers MM cell death via c-Jun upregulation.

D. Jäger, H. Goldschmidt, G. Tonon, 2014, Cancer letters.

Increased Sensitivity to DNA Damage Multiple Myeloma Cells Is Associated with Ku86 Variant Expression and Function in

Y. Shima, G. Teoh, D. Chauhan, 2013 .

Ku86 Variant Expression and Function in Multiple Myeloma Cells Is Associated with Increased Sensitivity to DNA Damage1

K. Anderson, Y. Shima, G. Teoh, 2000, The Journal of Immunology.

Effect of cachexia on bone turnover in cancer patients: a case-control study

K. Podar, H. Zwickl, M. Pecherstorfer, 2021, BMC cancer.

Therapeutics , Targets , and Chemical Biology GF-15 , a Novel Inhibitor of Centrosomal Clustering , Suppresses Tumor Cell Growth In Vitro and In Vivo

H. Goldschmidt, K. Anderson, U. Haberkorn, 2012 .

Identification of genes regulated by Dexamethasone in multiple myeloma cells using oligonucleotide arrays

K. Anderson, D. Auclair, N. Munshi, 2002, Oncogene.

Dephosphorylation of Ser-259 Regulates Raf-1 Membrane Association*

M. Pacher, K. Podar, M. Baccarini, 2002, The Journal of Biological Chemistry.

Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341.

K. Anderson, N. Munshi, P. Richardson, 2003, Blood.

Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells

K. Anderson, N. Munshi, P. Richardson, 2007, British journal of haematology.

Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells.

K. Anderson, N. Munshi, P. Richardson, 2009, Blood.

Relapsed/Refractory Multiple Myeloma in 2020/2021 and Beyond

K. Podar, X. Leleu, 2021, Cancers.

Honokiol overcomes conventional drug resistance in human multiple myeloma by induction of caspase-dependent and -independent apoptosis.

K. Anderson, P. Richardson, J. Arbiser, 2004, Blood.

RANK‐Fc in myeloma

K. Anderson, N. Munshi, P. Richardson, 2002, Cancer research.

of the Myc and Pim proto-oncogenes requires a functional FERM domain for transformation and for expression The Jak2V617F oncogene associated with myeloproliferative diseases

S. Constantinescu, J. Griffin, D. Gilliland, 2013 .

The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes.

M. Tomasson, S. Constantinescu, J. Griffin, 2008, Blood.

Activated Jak2 with the V617F Point Mutation Promotes G1/S Phase Transition*

D. Neuberg, J. Griffin, Jessica L. Gramlich, 2006, Journal of Biological Chemistry.

Insulin-like growth factor-1 induces adhesion and migration in human multiple myeloma cells via activation of beta1-integrin and phosphatidylinositol 3'-kinase/AKT signaling.

K. Anderson, N. Munshi, P. Richardson, 2003, Cancer research.

Caveolin-1 as a potential new therapeutic target in multiple myeloma.

K. Anderson, K. Podar, K. Anderson, 2006, Cancer letters.

A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells.

K. Anderson, P. Richardson, N. Mitsiades, 2005, Cancer research.

2-Methoxyestradiol overcomes drug resistance in multiple myeloma cells.

K. Anderson, N. Munshi, P. Richardson, 2002, Blood.

Antitumor activity of lysophosphatidic acid acyltransferase-beta inhibitors, a novel class of agents, in multiple myeloma.

K. Anderson, N. Munshi, P. Richardson, 2003, Cancer research.

Emerging Therapies for Multiple Myeloma

K. Anderson, P. Richardson, D. Chauhan, 2006, Expert opinion on emerging drugs.

inhibitor PS-341 Molecular mechanisms mediating antimyeloma activity of proteasome

K. Anderson, N. Munshi, P. Richardson, 2013 .

Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma.

N. Munshi, P. Richardson, D. Chauhan, 2007, Blood.

Identiﬁcation of novel antigens with induced immune response in monoclonal gammopathy of undetermined signiﬁcance

N. Munshi, P. Tassone, C. Mitsiades, 2009 .

Identification of novel antigens with induced immune response in monoclonal gammopathy of undetermined significance.

N. Munshi, P. Tassone, C. Mitsiades, 2009, Blood.

Human anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myeloma.

N. Munshi, P. Richardson, T. Hideshima, 2005, Cancer research.

Cells : Clinical Implications Antibody , Induces Cytotoxicity in Human Multiple Myeloma Mechanisms by which SGN-40 , a Humanized Anti-CD 40

N. Munshi, P. Richardson, C. Mitsiades, 2004 .

Translocation of Ku86/Ku70 to the multiple myeloma cell membrane: functional implications.

Fengfei Wang, Y. Tai, K. Podar, 2002, Experimental hematology.

The biological sequelae of stromal cell-derived factor-1alpha in multiple myeloma.

N. Munshi, P. Richardson, D. Chauhan, 2002, Molecular cancer therapeutics.

apoptosis myeloma by induction of caspase-dependent and -independent Honokiol overcomes conventional drug resistance in human multiple

P. Richardson, J. Arbiser, Shaji K. Kumar, 2010 .

A pivotal role for Mcl-1 in Bortezomib-induced apoptosis

M. Amiot, J. Opferman, Jing Zhang, 2008, Oncogene.

Molecular characterization of PS-341 (bortezomib) resistance: implications for overcoming resistance using lysophosphatidic acid acyltransferase (LPAAT)-β inhibitors

N. Munshi, P. Richardson, Shaji K. Kumar, 2005, Oncogene.

Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma

N. Munshi, P. Richardson, N. Mitsiades, 2003, Oncogene.

Transforming growth factor beta receptor I kinase inhibitor down-regulates cytokine secretion and multiple myeloma cell growth in the bone marrow microenvironment.

P. Richardson, D. Chauhan, T. Hideshima, 2004, Clinical cancer research : an official journal of the American Association for Cancer Research.

Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application

P. Richardson, Shaji K. Kumar, D. Chauhan, 2005, British journal of haematology.

Increased Sensitivity to DNA Damage Multiple Myeloma Cells Is Associated with Ku86 Variant Expression and Function in

Y. Shima, G. Teoh, D. Chauhan, 2013 .

Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target.

N. Munshi, P. Richardson, Shaji K. Kumar, 2009, Cancer cell.

Insulin-like Growth Factor-1 Induces Adhesion and Migration in Human Multiple Myeloma Cells via Activation of 1-Integrin and Phosphatidylinositol 3-Kinase / AKT Signaling 1

N. Munshi, P. Richardson, N. Mitsiades, 2003 .

MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts.

M. Boccadoro, N. Raje, T. Hideshima, 2007, Blood.

Receptor activator of nuclear factor-kappa B (RANK) ligand expression: In human multiple myeloma cells.

N. Munshi, P. Richardson, N. Mitsiades, 2001 .

The PKC- Inhibitor Enzastaurin Inhibits MM Cell Growth, Survival and Migration in the Bone Marrow Microenvironment.

N. Munshi, D. Chauhan, T. Hideshima, 2005 .

Multiple myeloma

P. Richardson, K. Podar, M. Raab, 2009, The Lancet.

Preclinical efficacy of sepantronium bromide (YM155) in multiple myeloma is conferred by down regulation of Mcl-1

B. Klein, D. Hose, H. Goldschmidt, 2014, Oncotarget.

Patupilone (epothilone B) inhibits growth and survival of multiple myeloma cells in vitro and in vivo.

C. Mitsiades, J. Griffin, D. Chauhan, 2005, Blood.

Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis.

N. Munshi, P. Richardson, P. Tassone, 2007, Blood.

Efficacy of Subcutaneous Bortezomib in the Management of Patients with Multiple Myeloma or Relapsed Mantle Cell Lymphoma

K. Podar, 2014 .

Bortezomib induces canonical nuclear factor- (cid:1) B activation in multiple myeloma cells

N. Munshi, P. Richardson, D. Chauhan, 2009 .

MLN120B, a Novel IKBKinase B Inhibitor, Blocks Multiple Myeloma Cell Growth In vitro and In vivo

N. Munshi, L. Dang, D. Chauhan, 2006 .

MLN 120 B , a Novel I K BKinase B Inhibitor , Blocks Multiple Myeloma Cell Growth In vitro and In vivo

N. Munshi, L. Dang, P. Richardson, 2006 .

β-lapachone, a novel plant product, overcomes drug resistance in human multiple myeloma cells

N. Munshi, N. Mitsiades, C. Mitsiades, 2002 .

The Biological Sequelae of Stromal Cell-derived Factor-1 (cid:1) in Multiple Myeloma 1

N. Munshi, P. Richardson, T. Hayashi, 2002 .

Novel inosine monophosphate dehydrogenase inhibitor VX-944 induces apoptosis in multiple myeloma cells primarily via caspase-independent AIF/Endo G pathway

Shaji K. Kumar, D. Chauhan, N. Raje, 2005, Oncogene.

Bone marrow microenvironment- induced regulation of Bcl-2 family members in multiple myeloma (MM): Therapeutic implications.

K. Podar, S. Vallet, Osman Aksoy, 2022, Cytokine.

Toward optimizing pomalidomide therapy in MM patients.

K. Podar, 2015, Blood.

synergistic activity in multiple myeloma Combination of the mTOR inhibitor rapamycin and CC-5013 has

N. Munshi, P. Richardson, Shaji K. Kumar, 2013 .

Combination of the mTOR inhibitor Rapamycin and Revlimid ( CC-5013 ) has synergistic activity in Multiple Myeloma

N. Munshi, P. Richardson, C. Mitsiades, 2004 .

Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications.

N. Munshi, P. Richardson, D. Chauhan, 2005, Cancer research.

MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo.

N. Munshi, L. Dang, P. Richardson, 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

Activation of the PI3K/mTOR pathway by BCR-ABL contributes to increased production of reactive oxygen species.

R. Salgia, J. Griffin, D. Chauhan, 2005, Blood.

Biologic sequelae of I{kappa}B kinase (IKK) inhibition in multiple myeloma: therapeutic implications.

A. Protopopov, N. Munshi, P. Richardson, 2009, Blood.

TGF-β Receptor I Kinase Inhibitor Downregulates Cytokine Secretion and Multiple Myeloma Cell Growth in the Bone Marrow Microenvironment.

P. Richardson, D. Chauhan, T. Hideshima, 2004 .

Choosing an appropriate salvage therapy for a patient with multiple myeloma

K. Podar, 2018, Expert opinion on pharmacotherapy.

Heat shock protein-27 confers drug-resistance in multiple myeloma cells.

K. Anderson, P. Richardson, N. Mitsiades, 2002 .

JunB is a key regulator of multiple myeloma bone marrow angiogenesis

E. Wagner, D. Hose, H. Goldschmidt, 2021, Leukemia.

Vascular Endothelial Growth Factor-induced Migration of Multiple Myeloma Cells Is Associated with β1 Integrin- and Phosphatidylinositol 3-Kinase-dependent PKCα Activation*

Kenneth C. Anderson, Ravi Salgia, Takashi Kijima, 2002, The Journal of Biological Chemistry.

GF-15, a novel inhibitor of centrosomal clustering, suppresses tumor cell growth in vitro and in vivo.

H. Goldschmidt, U. Haberkorn, A. Krämer, 2012, Cancer research.

Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration.

K. Anderson, P. Richardson, C. Mitsiades, 2001, Blood.

Raf-1-associated Protein Phosphatase 2A as a Positive Regulator of Kinase Activation*

W. Kolch, H. Mischak, M. Pacher, 2000, The Journal of Biological Chemistry.

Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma.

M. Dimopoulos, S. Jagannath, S. Lonial, 2019, The New England journal of medicine.

The therapeutic role of targeting protein kinase C in solid and hematologic malignancies

D. Chauhan, K. Podar, M. Raab, 2007, Expert opinion on investigational drugs.

CS1 promotes multiple myeloma cell adhesion, clonogenic growth, and tumorigenicity via c-maf-mediated interactions with bone marrow stromal cells.

G. Tonon, N. Munshi, P. Burger, 2008, Blood.

A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib.

Hiroshi Yasui, Paul Richardson, Benjamin Nicholson, 2005, Cancer cell.

Mcl-1 confers protection of Her2-positive breast cancer cells to hypoxia: therapeutic implications

A. Schneeweiss, D. Jäger, J. Opferman, 2016, Breast Cancer Research.

Targeting the Bone Marrow Microenvironment.

K. Podar, M. Moschetta, Y. Kawano, 2016, Cancer treatment and research.

New insights, recent advances, and current challenges in the biological treatment of multiple myeloma

K. Podar, S. Vallet, 2013, Expert opinion on biological therapy.

The AP-1 transcription factor JunB is essential for multiple myeloma cell proliferation and drug resistance in the bone marrow microenvironment

E. Wagner, D. Hose, H. Goldschmidt, 2017, Leukemia.

Targeting the Tumor Microenvironment: Focus on Angiogenesis

K. Podar, D. Jaeger, F. Fan, 2011, Journal of oncology.

Critical role for Gab2 in transformation by BCR/ABL.

H. Iwasaki, B. Neel, J. Griffin, 2002, Cancer cell.

Janus kinase inhibitor INCB20 has antiproliferative and apoptotic effects on human myeloma cells in vitro and in vivo

P. Tassone, J. Fridman, D. Chauhan, 2009, Molecular Cancer Therapeutics.

Combination Therapy with Interleukin-6 Receptor Superantagonist Sant7 and Dexamethasone Induces Antitumor Effects in a Novel SCID-hu In vivo Model of Human Multiple Myeloma

N. Munshi, R. Savino, P. Tassone, 2005, Clinical Cancer Research.

CD40 induces human multiple myeloma cell migration via phosphatidylinositol 3-kinase/AKT/NF-kappa B signaling.

N. Munshi, N. Mitsiades, C. Mitsiades, 2003, Blood.

A novel Bcl-2/Bcl-XL/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma

N. Munshi, P. Richardson, D. Chauhan, 2007, Oncogene.

1 VEGF INDUCES MCL-1 UPREGULATION AND PROTECTS MULTIPLE MYELOMA CELLS AGAINST APOPTOSIS

M. Amiot, P. Richardson, Shaji K. Kumar, 2004 .

Hsp27 inhibits release of mitochondrial protein Smac in multiple myeloma cells and confers dexamethasone resistance.

N. Munshi, N. Mitsiades, C. Mitsiades, 2003, Blood.

A therapeutic role for targeting c-Myc/Hif-1-dependent signaling pathways.

K. Podar, K. Anderson, 2010, Cell cycle.

Targeting mitochondria to overcome conventional and bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cells.

N. Munshi, P. Richardson, C. Mitsiades, 2004, Blood.

proteasome inhibitor PS-341 resistance in multiple Targeting mitochondria to overcome conventional and

N. Munshi, P. Richardson, C. Mitsiades, 2004 .

JNK-dependent Release of Mitochondrial Protein, Smac, during Apoptosis in Multiple Myeloma (MM) Cells*

N. Munshi, N. Mitsiades, C. Mitsiades, 2003, The Journal of Biological Chemistry.

Emerging protein kinase inhibitors for the treatment of multiple myeloma

K. Podar, S. Vallet, J. Lind, 2019, Expert opinion on emerging drugs.

Cytokines and signal transduction.

D. Chauhan, T. Hideshima, K. Podar, 2005, Best practice & research. Clinical haematology.

Inhibition of the TGF-β Signaling Pathway in Tumor Cells

N. Raje, K. Podar, K. Anderson, 2007 .

Transforming Growth Factor β Receptor I Kinase Inhibitor Down-Regulates Cytokine Secretion and Multiple Myeloma Cell Growth in the Bone Marrow Microenvironment

P. Richardson, D. Chauhan, T. Hideshima, 2004, Clinical Cancer Research.

antitumor activity in Waldenström macroglobulinemia Protein kinase C inhibitor enzastaurin induces in vitro and in vivo

S. Treon, T. Hideshima, A. Leontovich, 2008 .

Protein kinase C inhibitor enzastaurin induces in vitro and in vivo antitumor activity in Waldenstrom macroglobulinemia.

S. Treon, T. Hideshima, A. Leontovich, 2007, Blood.

against apoptosis VEGF induces MCL-1 upregulation and protects multiple myeloma cells

M. Amiot, P. Richardson, Shaji K. Kumar, 2013 .

MLN120B, a Novel IκB Kinase β Inhibitor, Blocks Multiple Myeloma Cell Growth In vitro and In vivo

Hiroshi Yasui, Kenneth C. Anderson, Paul G. Richardson, 2006, Clinical Cancer Research.

FTY720 induces apoptosis in multiple myeloma cells and overcomes drug resistance.

P. Richardson, C. Mitsiades, Shaji K. Kumar, 2005, Cancer research.

SDX-101, the R-enantiomer of etodolac, induces cytotoxicity, overcomes drug resistance, and enhances the activity of dexamethasone in multiple myeloma.

N. Munshi, P. Tassone, Shaji K. Kumar, 2005, Blood.

Targeting signalling pathways for the treatment of multiple myeloma

D. Chauhan, T. Hideshima, K. Podar, 2005, Expert opinion on therapeutic targets.

Mcl-1 Regulation and Its Role in Multiple Myeloma

K. Podar, J. Harousseau, S. Gouill, 2004, Cell cycle.

Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM).

N. Munshi, P. Richardson, P. Tassone, 2004, Blood.

The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications.

K. Podar, K. Anderson, 2005, Blood.

Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment.

N. Munshi, P. Richardson, D. Chauhan, 2006, Cancer research.

Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma.

Paul Richardson, N. Munshi, P. Richardson, 2004, Blood.

Targeting PKC: a novel role for beta-catenin in ER stress and apoptotic signaling.

G. Tonon, N. Munshi, D. Chauhan, 2008, Blood.

Critical Role for Hematopoietic Cell Kinase (Hck)-mediated Phosphorylation of Gab1 and Gab2 Docking Proteins in Interleukin 6-induced Proliferation and Survival of Multiple Myeloma Cells*

R. Mulligan, D. Chauhan, T. Hideshima, 2004, Journal of Biological Chemistry.

Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implications.

N. Munshi, P. Richardson, C. Mitsiades, 2004, Cancer research.

Rationally derived drug combinations with the novel Mcl-1 inhibitor EU-5346 in breast cancer

A. Schneeweiss, D. Jäger, J. Opferman, 2018, Breast Cancer Research and Treatment.

Inhibition of VEGF Signaling Pathways in Multiple Myeloma and Other Malignancies

K. Podar, Klaus Podar, Kenneth C Anderson, 2007, Cell cycle.

Inhibitors of the Transcription Factor STAT3 Decrease Growth and Induce Immune Response Genes in Models of Malignant Pleural Mesothelioma (MPM)

C. Paweletz, R. Bueno, R. Salgia, 2020, Cancers.

BIRB 796 enhances cytotoxicity triggered by bortezomib, heat shock protein (Hsp) 90 inhibitor, and dexamethasone via inhibition of p38 mitogen‐activated protein kinase/Hsp27 pathway in multiple myeloma cell lines and inhibits paracrine tumour growth

Hiroshi Yasui, P. Richardson, C. Pargellis, 2007, British journal of haematology.

Effects of PKC412, nilotinib, and imatinib against GIST-associated PDGFRA mutants with differential imatinib sensitivity.

D. Fabbro, J. Griffin, A. Kung, 2006, Gastroenterology.

Caveolin-1 Is Required for Vascular Endothelial Growth Factor-Triggered Multiple Myeloma Cell Migration and Is Targeted by Bortezomib

P. Richardson, D. Chauhan, T. Hideshima, 2004, Cancer Research.

Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma.

G. Morgan, P. Richardson, D. Chauhan, 2001, Blood.

Bone marrow microenvironment and the identification of new targets for myeloma therapy

D. Chauhan, K. Podar, K. Anderson, 2009, Leukemia.

The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma

G. Tonon, Shaji K. Kumar, D. Chauhan, 2006, Proceedings of the National Academy of Sciences.

Essential Role of Caveolae in Interleukin-6- and Insulin-like Growth Factor I-triggered Akt-1-mediated Survival of Multiple Myeloma Cells*

G. Morgan, N. Munshi, N. Mitsiades, 2003, The Journal of Biological Chemistry.

A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase.

J. Christensen, R. Salgia, P. Ma, 2003, Cancer research.

Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications

P. Richardson, Lei Wu, Y. Shima, 2001, Leukemia.

Targeting the vascular endothelial growth factor pathway in the treatment of multiple myeloma

P. Richardson, D. Chauhan, K. Podar, 2007, Expert review of anticancer therapy.

BCR-ABL promotes the frequency of mutagenic single-strand annealing DNA repair.

J. Griffin, D. Weinstock, K. Podar, 2009, Blood.

Blockade of Hsp27 overcomes Bortezomib/proteasome inhibitor PS-341 resistance in lymphoma cells.

D. Chauhan, T. Hideshima, K. Podar, 2003, Cancer research.

Preclinical activity of P276-00, a novel small-molecule cyclin-dependent kinase inhibitor in the therapy of multiple myeloma

N. Munshi, P. Richardson, D. Scadden, 2009, Leukemia.

Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti‐myeloma activity in vitro and in vivo

N. Munshi, P. Richardson, P. Burger, 2010, British journal of haematology.

Pathological glycogenesis through glycogen synthase 1 and suppression of excessive AMP kinase activity in myeloid leukemia cells

D. Neuberg, G. Tonon, J. Asara, 2015, Leukemia.

Targeting transcription factors in multiple myeloma: evolving therapeutic strategies

A. Roccaro, A. Sacco, K. Podar, 2019, Expert opinion on investigational drugs.

Pathway-Directed Therapy in Multiple Myeloma

K. Podar, M. Raab, M. Krauth, 2021, Cancers.

Selinexor for the treatment of multiple myeloma

J. Shah, S. Jagannath, P. Richardson, 2020, Expert opinion on pharmacotherapy.

secretion in human multiple myeloma cells CD40 activation induces p53-dependent vascular endothelial growth factor

Y. Tai, K. Podar, M. Akiyama, 2013 .

CD40 activation induces p53-dependent vascular endothelial growth factor secretion in human multiple myeloma cells.

Y. Tai, K. Podar, M. Akiyama, 2002, Blood.

CD 40 activation induces p 53-dependent vascular endothelial growth factor secretion in human multiple myeloma cells

Y. Tai, K. Podar, M. Akiyama, 2002 .

The malignant clone and the bone-marrow environment.

P. Richardson, D. Chauhan, T. Hideshima, 2007, Best practice & research. Clinical haematology.

Novel Transforming Mutations of CBL in Human Acute Myeloid Leukemia

R. Salgia, J. Griffin, H. Band, 2008 .

Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells.

Hiroshi Yasui, N. Munshi, P. Richardson, 2005, Blood.

The Role of AP-1 Transcription Factors in Plasma Cell Biology and Multiple Myeloma Pathophysiology

K. Podar, F. Fan, Fengjuan Fan, 2021, Cancers.

Current and developing synthetic pharmacotherapy for treating relapsed/refractory multiple myeloma

K. Podar, M. Pecherstorfer, 2017, Expert opinion on pharmacotherapy.

Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu.

N. Munshi, P. Richardson, P. Burger, 2008, Blood.

Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies

K. Podar, D. Jaeger, M. Witzens‐Harig, 2012, Expert opinion on pharmacotherapy.

Pre-Osteoblasts Stimulate Migration of Breast Cancer Cells via the HGF/MET Pathway

A. Schneeweiss, D. Jäger, K. Podar, 2016, PloS one.

Essential role of the histone lysine demethylase KDM4A in the biology of malignant pleural mesothelioma (MPM)

R. Bueno, Prakash Kulkarni, R. Salgia, 2021, British Journal of Cancer.

Targeting Multiple Myeloma Tumor Angiogenesis: Focus on VEGF

K. Podar, K. Anderson, 2013 .

The selective adhesion molecule inhibitor Natalizumab decreases multiple myeloma cell growth in the bone marrow microenvironment: therapeutic implications

N. Halama, D. Jäger, G. Tonon, 2011, British journal of haematology.

Prolyl Hydroxylase 3 Attenuates MCL-1-Mediated ATP Production to Suppress the Metastatic Potential of Colorectal Cancer Cells.

J. Opferman, M. Mollenhauer, J. Weitz, 2016, Cancer research.

A role for bone turnover markers β-CrossLaps (CTX) and amino-terminal propeptide of type I collagen (PINP) as potential indicators for disease progression from MGUS to multiple myeloma

R. Kyle, K. Podar, M. Pecherstorfer, 2018, Leukemia & lymphoma.

Acute myeloid leukemia cells require 6-phosphogluconate dehydrogenase for cell growth and NADPH-dependent metabolic reprogramming

D. Neuberg, R. Salgia, J. Griffin, 2017, Oncotarget.

Novel Oncogenic Mutations of CBL in Human Acute Myeloid Leukemia That Activate Growth and Survival Pathways Depend on Increased Metabolism*

R. Larson, M. Carroll, R. Salgia, 2010, The Journal of Biological Chemistry.

Identification of genes regulated by 2-methoxyestradiol (2ME2) in multiple myeloma cells using oligonucleotide arrays.

W. Wong, D. Auclair, N. Munshi, 2003, Blood.

On the continuous (R)evolution of antibody-based and CAR T cell therapies in multiple myeloma: an early 2022 glance into the future

K. Podar, M. Pecherstorfer, S. Vallet, 2022, Expert opinion on pharmacotherapy.

Novel etodolac analog SDX-308 (CEP-18082) induces cytotoxicity in multiple myeloma cells associated with inhibition of β-catenin/TCF pathway

D. Carrasco, K. Sukhdeo, P. Richardson, 2007, Leukemia.

Myeloma Bone Disease: Update on Pathogenesis and Novel Treatment Strategies

K. Podar, M. Pecherstorfer, S. Vallet, 2018, Pharmaceutics.

synergistic cytotoxicity in multiple myeloma vivo in Combination of proteasome inhibitors bortezomib and NPI-0052 trigger

N. Munshi, P. Richardson, D. Chauhan, 2012 .

Targeting the Ubiquitin-proteasome system for the Treatment of Multiple Myeloma and Other Human Diseases

K. Podar, K. Anderson, 2010 .

in vivo synergistic cytotoxicity in multiple myeloma Combination of proteasome inhibitors bortezomib and NPI-0052 trigger

N. Munshi, D. Chauhan, T. Hideshima, 2008 .

Targeting PKC in multiple myeloma: in vitro and in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY317615.HCl).

N. Munshi, D. McMillin, D. Chauhan, 2006, Blood.

Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo

T. Hideshima, F. Davies, K. Podar, 2003, Leukemia.

Targeting angiogenesis via a c-Myc/hypoxia-inducible factor-1alpha-dependent pathway in multiple myeloma.

G. Tonon, S. Lababidi, D. Chauhan, 2009, Cancer research.

Proteasomal Degradation of Topoisomerase I Is Preceded by c-Jun NH2-Terminal Kinase Activation, Fas Up-Regulation, and Poly(ADP-Ribose) Polymerase Cleavage in SN38-Mediated Cytotoxicity against Multiple Myeloma

N. Munshi, P. Richardson, P. Tassone, 2004, Cancer Research.

stromal cells mediated interactions with bone marrow - tumorigenicity via c-maf CS1 promotes multiple myeloma cell adhesion, clonogenic growth, and

G. Tonon, N. Munshi, P. Burger, 2013 .

The Evolution and Maintenance of the Multiple Myeloma Cell Clone within the Liquid Bone Marrow Compartment: Therapeutic Implications

K. Podar, K. Anderson, 2010 .

The Pathophysiologic Role of the Bone Marrow Environment and its Niches in Multiple Myeloma

K. Podar, K. Anderson, 2010 .

Up-regulation of c-Jun inhibits proliferation and induces apoptosis via caspase-triggered c-Abl cleavage in human multiple myeloma.

G. Tonon, R. DePinho, D. Chauhan, 2007, Cancer research.

MM-associated anemia: more than "crowding out" HSPCs.

K. Podar, 2012, Blood.

Novel therapies targeting the myeloma cell and its bone marrow microenvironment.

P. Richardson, D. Chauhan, T. Hideshima, 2001, Seminars in oncology.

Ask the Experts: Deriving new treatment strategies in multiple myeloma

K. Podar, 2012 .

Deriving new treatment strategies in multiple myeloma

K. Podar, 2012 .

Niches Within the Multiple Myeloma Bone Marrow Microenvironment

D. Chauhan, T. Hideshima, K. Podar, 2007 .

Multiple Myeloma - a New Era of Treatment Strategies

G. Tonon, S. Lonial, D. Ribatti, 2012 .

GW654652, the pan-inhibitor of VEGF receptors, blocks the growth and migration of multiple myeloma cells in the bone marrow microenvironment.

P. Richardson, D. Chauhan, T. Hideshima, 2004, Blood.

Atiprimod (N-N-diethl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) Inhibits Myeloma in Vivo.

N. Munshi, P. Richardson, P. Tassone, 2004 .

Evaluation of Antibody Responses in Patients with B-Cell Malignancies after Two and Three Doses of Anti-SARS-CoV-2 S Vaccination—A Retrospective Cohort Study

U. Jaeger, K. Podar, M. Pecherstorfer, 2023, Cancers.

Attrition Rates in Multiple Myeloma Treatment under Real World Conditions—An Analysis from the Austrian Myeloma Registry (AMR)

H. Ulmer, K. Podar, T. Winder, 2023, Cancers.

Targeting the Immune Niche within the Bone Marrow Microenvironment: The Rise of Immunotherapy in Multiple Myeloma.

K. Podar, D. Jāger, 2017, Current cancer drug targets.

Generation of Antitumor Invariant Natural Killer T Cell Lines in Multiple Myeloma and Promotion of Their Functions via Lenalidomide: A Strategy for Immunotherapy

N. Munshi, Y. Tai, M. Shammas, 2008, Clinical Cancer Research.

Evaluation of Antibody Responses to COVID-19 Vaccines among Solid Tumor and Hematologic Patients

K. Podar, M. Pecherstorfer, S. Vallet, 2021, Cancers.

The orally available multikinase inhibitor regorafenib (BAY 73-4506) in multiple myeloma

K. Podar, S. Wilhelm, M. Raab, 2018, Annals of Hematology.

Tissue Hypoxia and Alterations in Microvascular Architecture Predict Glioblastoma Recurrence in Humans

M. Buchfelder, I. Eyüpoglu, K. Podar, 2020, Clinical Cancer Research.

(LY317615.HCl) novel, orally available small-molecule inhibitor enzastaurin Targeting PKC in multiple myeloma: in vitro and in vivo effects of the

N. Munshi, D. McMillin, D. Chauhan, 2013 .

Adoptive cell therapy in multiple Myeloma

K. Podar, S. Vallet, Martin Pecherstorfer, 2017, Expert opinion on biological therapy.

Vascular endothelial growth factor-induced migration of multiple myeloma cells is associated with beta 1 integrin- and phosphatidylinositol 3-kinase-dependent PKC alpha activation.

Ravi Salgia, Takashi Kijima, R. Salgia, 2002, The Journal of biological chemistry.

2-Methoxyestardiol and bortezomib/proteasome-inhibitor overcome dexamethasone-resistance in multiple myeloma cells by modulating Heat Shock Protein-27

D. Auclair, N. Munshi, C. Mitsiades, 2004, Apoptosis.

CS1, a New Surface Target on Multiple Myeloma (MM) Cells, Protects Myeloma Cells from Apoptosis Via Regulation of ERK1/2, AKT and STAT3 Signaling Cascades.

G. Tonon, N. Munshi, P. Burger, 2007 .

beta-lapachone, a novel plant product, overcomes drug resistance in human multiple myeloma cells.

N. Munshi, N. Mitsiades, D. Chauhan, 2002, Experimental hematology.

Blockade of ubiquitin-conjugating enzyme CDC34 enhances anti-myeloma activity of Bortezomib/Proteasome inhibitor PS-341

N. Munshi, C. Mitsiades, D. Chauhan, 2004, Oncogene.

Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study

J. Breeze, M. Dimopoulos, R. Vij, 2021, BMC cancer.

Insulin-like growth factor-1 induces adhesion and migration in human multiple myeloma cells via activation of b1-integrin and phosphatidylinositol 3-kinase/AKT signaling beta.

N. Munshi, P. Richardson, N. Mitsiades, 2003 .

p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells

Constantine Mitsiades, P. Richardson, D. Chauhan, 2004, Oncogene.

Targeting Mcl-1 for Multiple Myeloma (MM) Therapy: Drug-Induced Generation of Mcl-1 Fragment Mcl-1128–350 Triggers MM Cell Death Via c- Jun Upregulation

H. Goldschmidt, G. Tonon, J. Opferman, 2012 .

Caveolin-1 Is Required for VEGF- Triggered Multiple Myeloma Cell Migration and Is Targeted by Bortezomib (Velcade®).

P. Richardson, D. Chauhan, T. Hideshima, 2004 .

Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study

J. Shah, J. Breeze, M. Dimopoulos, 2020, BMC Cancer.

Inhibition of the TGF-beta signaling pathway in tumor cells.

N. Raje, K. Podar, K. Anderson, 2007, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

FQPD, a novel immunomodulatory drug, has significant in vitro activity in multiple myeloma

N. Munshi, P. Richardson, Shaji K. Kumar, 2006, British journal of haematology.

Acute myeloid leukemia cells require 6-phosphogluconate dehydrogenase for cell growth and NADPH-dependent metabolic reprogramming

D. Neuberg, R. Salgia, J. Griffin, 2017, Oncotarget.

Novel targets and derived small molecule inhibitors in multiple myeloma.

K. Podar, 2012, Current cancer drug targets.

The AP-1 Transcription Factor JunB Promotes Multiple Myeloma (MM) Cell Proliferation, Survival and Drug Resistance in the Bone Marrow Microenvironment

E. Wagner, H. Goldschmidt, G. Tonon, 2014 .

CD 40 induces human multiple myeloma cell migration via phosphatidylinositol 3 – kinase / AKT / NF-B signaling

N. Munshi, N. Mitsiades, C. Mitsiades, 2003 .

apoptosis myeloma by induction of caspase-dependent and -independent Honokiol overcomes conventional drug resistance in human multiple

P. Richardson, J. Arbiser, Shaji K. Kumar, 2010 .

The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment

P. Richardson, J. Wood, Sigui Li, 2002, Cancer research.

In vitro and in vivo activity of the VEGF receptor inhibitor PAZOPANIB (GW786034) in Multiple Myeloma: Therapeutic implications.

G. Tonon, D. Chauhan, T. Hideshima, 2006 .

Effects of the indazolylpyrimidine GW786034 on angiogenesis and MM cell growth: Therapeutic implications.

P. Tassone, Shaji K. Kumar, D. Chauhan, 2004 .

P38 MAPK Inhibition Enhances PS-341 (bortezomib)-Induced Cytotoxicity Against Multiple Myeloma Cells.

Kenneth C. Anderson, Paul G. Richardson, Nikhil C. Munshi, 2004 .

The selective adhesion molecule inhibitor Natalizumab decreases multiple myeloma cell growth in the bone marrow microenvironment: therapeutic implications

N. Halama, D. Jäger, G. Tonon, 2011, British journal of haematology.

Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma.

G. Morgan, P. Richardson, D. Chauhan, 2001, Blood.

Targeting the Tumor Microenvironment: Focus on Angiogenesis

K. Podar, D. Jaeger, A. Schimming, 2011, Journal of oncology.

Targeting MEK1/2 Signaling Cascade by AS703026, a Novel Selective MEK1/2 Inhibitor, Induces Pleiotropic Anti-Myeloma Activity in Vitro and In Vivo.

N. Munshi, P. Richardson, P. Burger, 2009 .

GW654652, the pan-inhibitor of VEGF receptors, blocks the growth and migration of multiple myeloma cells in the bone marrow microenvironment.

P. Richardson, D. Chauhan, T. Hideshima, 2004, Blood.

Vascular Endothelial Growth Factor (VEGF) -induced migration of Multiple Myeloma cells is associated with ββββ 1-integrin- and PI3-kinase- dependent PKC αααα activation

D. Chauhan, K. Podar, M. Sattler, 2001 .

Targeting Mcl-1 for multiple myeloma (MM) therapy: drug-induced generation of Mcl-1 fragment Mcl-1(128-350) triggers MM cell death via c-Jun upregulation.

D. Jäger, H. Goldschmidt, G. Tonon, 2014, Cancer letters.

The Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor PTK 787 / ZK 222584 Inhibits Growth and Migration of Multiple Myeloma Cells in the Bone Marrow Microenvironment 1

N. Munshi, P. Richardson, J. Wood, 1998 .